Eye, Published online: 11 October 2025; doi:10.1038/s41433-025-04042-3Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatment

An 18-year-old man presented with rapid right eyelid swelling and proptosis for 1 month (A). He had retinal detachment surgery 2 years prior, with no tumor detected at that time. Magnetic resonance imaging revealed a right intraocular mass and diffuse orbital lesions involving the lacrimal gland and extraocular muscles (B). Gross examination showed a ciliary body tumor, firm and adherent to the sclera, extending to the posterior wall and into orbital tissues (C). Immunohistochemistry confirmed malignant uveal melanoma with positivity for Melan-A (D) and concurrent loss of integrase interactor-1 expression.

Publication date: Available online 10 October 2025 Source: Progress in Retinal and Eye Research Author(s): Kajal Agrawal, Ashley Shuen Ying Hong, Carlos Cifuentes-González, Vanitha Shyamili Kumar, William Rojas-Carabali, Shengjuan Zhang, Qingfeng Wang, Alejandra de-la-Torre, Marlies Gijs, Tejpal Gill, James T. Rosenbaum, Seesandra V. Rajagopala, Sapna Gangaputra, Alessandro Conforti, R.Paul Ross, Peizeng Yang, Sunny Wong, Rupesh Agrawal

Publication date: Available online 10 October 2025 Source: Experimental Eye Research Author(s): Pei-Liang Wu, Eugene Yu-Chuan Kang, Xiao Chun Ling, Chia-Wen Lee, Kuan-Jen Chen, Nan-Kai Wang, Laura Liu, Yih-Shiou Hwang, Chi-Chun Lai, Shun-Fa Yang, Wei-Chi Wu

Publication date: Available online 10 October 2025 Source: Experimental Eye Research Author(s): Mackenzie Browning, Robyn McCartan, Arissa Gratkowski, Daniel Paris, Andrew Pearson, Alexander Morin, Scott Ferguson, Larry Brown, Howard Wessel, Radouil Tzekov, Michael Mullan, Fiona Crawford, Benoit Mouzon

Eye, Published online: 11 October 2025; doi:10.1038/s41433-025-04070-zThe effect of ethnicity on the accuracy of fundal reflex referrals

.

.

The study herein explores the intricate relationship between these two major causes of vision loss worldwide: myopia and glaucoma.

The content on this site is intended for healthcare professionals. All content on this site: Copyright © 2025 Elsevier Inc., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

The content on this site is intended for healthcare professionals. All content on this site: Copyright © 2025 Elsevier Inc., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. The content on this site is intended for healthcare professionals. All content on this site: Copyright © 2025 Elsevier Inc., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. In this issue, Rabiolo and associates1 report on their literature review of criteria for failure in glaucoma surgery, stating that, compared with intraocular pressure (IOP) criteria, “Long-term visual field rates provide a more consistent primary outcome measure” and suggest that they “be incorporated into composite success criteria.” References 1. Evaluating high intraocular pressure criteria for failure in glaucoma surgery: Impact on estimated success and visual field rates Am J Ophthalmol. 2025; 2. Outcome measures for studies of glaucoma surgery Glaucoma Surgery: Open Angle Glaucoma 3. Consensus on definitions of success Guidelines on Design and Reporting of Glaucoma Surgical Trials 4. How clinical trial results are changing our thinking about target pressures Curr Opin Ophthalmol. 2002; 13:85-88 5. Laser in Glaucoma and Ocular Hyptertension (LiGHT) Trial: six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension Ophthalmology. 2023; 130:139-151 6. Applications of the water drinking test in glaucoma management Clin Exp Ophthalmol. 2017; 45:625-631

The content on this site is intended for healthcare professionals. All content on this site: Copyright © 2025 Elsevier Inc., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. The content on this site is intended for healthcare professionals. All content on this site: Copyright © 2025 Elsevier Inc., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. The content on this site is intended for healthcare professionals. All content on this site: Copyright © 2025 Elsevier Inc., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. In this issue, Rabiolo and associates1 report on their literature review of criteria for failure in glaucoma surgery, stating that, compared with intraocular pressure (IOP) criteria, “Long-term visual field rates provide a more consistent primary outcome measure” and suggest that they “be incorporated into composite success criteria.” References 1. Evaluating high intraocular pressure criteria for failure in glaucoma surgery: Impact on estimated success and visual field rates Am J Ophthalmol. 2025; 2. Outcome measures for studies of glaucoma surgery Glaucoma Surgery: Open Angle Glaucoma 3. Consensus on definitions of success Guidelines on Design and Reporting of Glaucoma Surgical Trials 4. How clinical trial results are changing our thinking about target pressures Curr Opin Ophthalmol. 2002; 13:85-88 5. Laser in Glaucoma and Ocular Hyptertension (LiGHT) Trial: six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension Ophthalmology. 2023; 130:139-151 6. Applications of the water drinking test in glaucoma management Clin Exp Ophthalmol. 2017; 45:625-631 HIGHLIGHTS Blue light-filtering IOLs did not reduce exudative age-related macular degeneration (AMD) risk in this large cohort study. Outcomes were comparable across sex, age, and history of nonexudative AMD. Abstract Purpose To evaluate whether blue light-filtering (BLF) intraocular lenses (IOLs) reduce the risk of exudative age-related macular degeneration (AMD). Design A nationwide, population-based cohort study using data from the Korean National Health Insurance Sharing Service (NHISS) database. Participants Individuals who underwent cataract surgery and received the same type of IOL (BLF or clear) in both eyes within one year between January 2012 and December 2018. Participants were categorized into BLF IOL or clear IOL groups, and the risk of exudative AMD was compared between the 2 groups. The 10-year cumulative incidence of exudative AMD was estimated using Kaplan-Meier analysis. Cox proportional hazard models and the Fine-Gray model were applied to calculate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs), adjusting for age, sex, socioeconomic status, and systemic diseases. The same analysis was performed in the cohort matched by age, sex, and the calendar year of the index date. Main outcome measures 10-year cumulative incidence, incidence rate, and HR for exudative AMD. A total of 21,741 individuals with BLF IOLs were compared to 56,357 individuals with clear IOLs. The mean follow-up duration was 7.0 ± 2.5 years in the BLF IOL group and 6.7 ± 2.5 years in the clear IOL group (P = .069). The 10-year cumulative incidence of exudative AMD was 1.8% (95% CI, 1.5%–2.0%) in the BLF IOL group and 1.7% (95% CI, 1.5%-1.8%) in the clear IOL group. The incidence rates per 100,000 person-years were 162.8 and 153.9 in the BLF IOL group and clear IOL groups, respectively, with no significant difference in the adjusted Cox model (aHR 1.12; 95% CI, 0.96-1.30; P = .149) and the Fine-Gray model (aHR 1.15; 95% CI, 0.97-1.36; P = .120). Subgroup analyses based on age, sex, and history of nonexudative AMD showed no protective effect of BLF IOLs, with comparable incidence rates across all subgroups. Similar results were observed in the matched cohort analysis. Conclusions BLF IOL implantation in cataract surgery does not reduce the risk of developing exudative AMD in the South Korean population, regardless of a history of nonexudative AMD.

To analyze nationwide preoperative gonioscopy utilization patterns for various glaucoma surgeries and laser surgeries over time using the IRISⓇ Registry (Intelligent Research in Sight).

Glaucoma is the leading cause of permanent blindness.1 This chronic optic nerve disorder is marked by the progressive degeneration of retinal ganglion cells, initially leading to peripheral vision loss, which may progress to affect central vision and ultimately result in complete blindness if not treated.2 Primary open-angle glaucoma (POAG) is the one of the most prevalent forms, with an estimated prevalence of 1% to 2% among individuals aged 40 and above.3 As the global population continues to age, the incidence of POAG is anticipated to increase, maintaining its status as a significant health issue worldwide.

Corneal dystrophy is a collection of hereditary ocular diseases characterized by progressive abnormal deposition of substances in the cornea, leading to visual impairment and episodic pain.1 Fuchs endothelial corneal dystrophy, the most common form, affects approximately 4% of individuals over 40 in the United States, with prevalence increasing with age.2 Symptoms range from asymptomatic cases to significant visual acuity loss, photophobia, corneal edema, and recurrent corneal erosions.1,3 These disturbances can disrupt daily activities and diminish quality of life.

To characterize axial length (AL) growth trajectories in children who developed myopia compared with children who remained nonmyopic.

Patients with non-infectious intermediate, posterior, or panuveitides typically are treated with oral corticosteroids and immunosuppressive agents, such as antimetabolites and calcineurin inhibitors. Goals of treatment include suppression of ocular inflammation (inactive disease) and reduction of oral corticosteroids to a prednisone dose

BOSTON — A statistically significant increase in tear volume and lipid concentration was seen 3 minutes after instillation of a single drop of Tryptyr in patients with dry eye disease, according to research presented at Academy 2025. Nate Lighthizer, OD, FAAO, FAAOMS, assistant dean and associate professor at the College of Optometry at Northeastern State University in Tahlequah, Oklahoma, presented a poster outlining the phase 3b study of Tryptyr (acoltremon ophthalmic solution 0.003%, Alcon), which stimulates TRPM8 receptors to activate the trigeminal nerve, leading to increased

BOSTON — A real-world Canadian study of Diffusion Optics Technology lenses by SightGlass Vision showed that they slowed myopia progression to near emmetropic levels among children aged 6 to 10 years, according to data presented here. “In Canada, we have an arsenal of tools for combating myopia, such as [orthokeratology], soft contact lenses, myopic defocus lenses and DOT lenses,” Kylvin Ho, OD, FIAOMC, of CU Vision Optometrists, told Healio at the Academy 2025 meeting. “In this study we want to see how our patients who have worn at least 2 years of this particular DOT

Editor’s note: This is a developing news story. Please check back soon for updates. The FDA approved Eydenzelt, a biosimilar referencing Eylea, for the treatment of four retinal diseases, according to a press release from Celltrion. These conditions include wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy. According to the release, the FDA based its decision on Eydenzelt (aflibercept-boav) on analytical, nonclinical and clinical data. Notably, a randomized, double-masked, parallel-group, multicenter, 52-week

BOSTON — A study of atropine eye drops to delay the onset of pediatric myopia has received federal grants totaling $25 million and will be conducted by researchers at the University of Houston and The Ohio State University. “A study like this has never been conducted in the United States,” David A. Berntsen, OD, PhD, FAAO, coprincipal investigator and Golden-Golden Professor of Optometry at the University of Houston, told Healio during Academy 2025. “If we’re able to find these kids and provide a treatment that’s able to delay when they become nearsighted, our hope is that we can decrease how

BOSTON — A study of atropine eye drops to delay the onset of pediatric myopia has received federal grants totaling $25 million and will be conducted by researchers at the University of Houston and The Ohio State University. “A study like this has never been conducted in the United States,” David A. Berntsen, OD, PhD, FAAO, coprincipal investigator and Golden-Golden Professor of Optometry at the University of Houston, told Healio during Academy 2025. “If we’re able to find these kids and provide a treatment that’s able to delay when they become nearsighted, our hope is that we can decrease how

BOSTON — A study of atropine eye drops to delay the onset of pediatric myopia has received federal grants totaling $25 million and will be conducted by researchers at the University of Houston and The Ohio State University. “A study like this has never been conducted in the United States,” David A. Berntsen, OD, PhD, FAAO, coprincipal investigator and Golden-Golden Professor of Optometry at the University of Houston, told Healio during Academy 2025. “If we’re able to find these kids and provide a treatment that’s able to delay when they become nearsighted, our hope is that we can decrease how

BOSTON — A study of atropine eye drops to delay the onset of pediatric myopia has received federal grants totaling $25 million and will be conducted by researchers at the University of Houston and The Ohio State University. “A study like this has never been conducted in the United States,” David A. Berntsen, OD, PhD, FAAO, coprincipal investigator and Golden-Golden Professor of Optometry at the University of Houston, told Healio during Academy 2025. “If we’re able to find these kids and provide a treatment that’s able to delay when they become nearsighted, our hope is that we can decrease how

Eye, Published online: 10 October 2025; doi:10.1038/s41433-025-04035-2Drug-related retinal detachment pharmacovigilance signals in the real world: evidence from the FDA Adverse Event Reporting System